Intriguingly, it has been seen that driver fusions in lung adenocarcinomas co-occur with SETD2 mutations (16% of cases) in contrast with lung adenocarcinomas with EGFR, KRAS, BRAF and MET mutations, where the frequency of SETD2 mutations is only 2% [10]. This evidence concerns the gene BRAF and lung adenocarcinoma.